Blood pressure reduction associated with preservation of renal function in hypertensive patients with IgA nephropathy: A 3-year follow-up

Clinical Nephrology

Volumn 54, Issue 5, 2000, Pages 360-365

  Kanno, Y ^a   Okada, H ^a   Saruta, T ^a   Suzuki, H ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Blood pressure reduction; Hypertensives; Renal function

Indexed keywords

AMLODIPINE; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; JAPAN; KIDNEY FUNCTION; MALE; PROTEINURIA; SIDE EFFECT;

ADULT; AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZAZEPINES; CALCIUM CHANNEL BLOCKERS; CREATININE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, IGA; HUMANS; HYPERTENSION; MALE;

EID: 0033777626     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Angiotensin-converting enzyme inhibitors in young patients with IgA nephropathy: Effects against deteroration of renal function
2. Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy
3. Long-term benefits of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy: A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy
4. Ambulatory blood pressure monitoring and progression in patients with IgA nephropathy
5. The commonest glomerulonephritis in the world: IgA nephropathy
6. IgA nephropathy: Morphologic expression and pathogenesis
7. Angiotensin-converting enzyme inhibition and renal protection: An assessment of implications for therapy
8. Alternate-day prednisone therapy in IgA nephropathy. Preliminary analysis of a prospective, randomized, controlled trial
9. Captopril and renal survival in patients with human immunodeficiency virus nephropathy
10. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease
11. Association between blood pressure and the rate of decline in renal function with age
12. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: A multicentre, randomized, placebo-controlled study
13. Histological alterations in renal specimens as indicators of prognosis of IgA nephropathy
14. Effect of increasing doses of lisinopril on proteinuria of normotensive patients with IgA nephropathy and normal renal function
15. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin
16. Means of clinical evaluation of renal disease progression
17. Deterioration rate in hypertensive IgA nephropathy: Comparison of a converting enzyme inhibitor and beta blocking agents
18. Additive anti-proteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy
19. A retrospective analysis of the natural history of primary IgA nephropathy worldwide
20. Role of calcium channel blockers in protection against experimental renal injury
21. The 1988 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure
22. Circadian blood pressure changes in patients with chronic renal insufficiency: A prospective study
23. Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure
24. Antihypertensive drugs, dietary salt, and renal protection: How low should you go and with which therapy?
25. Role of the deletion of polymorphism of the angiotensin-converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy
26. Long-term comparison between captoril and nifedipine in the progression of renal insufficiency